Sutedja T, Baas P, Stewart F, van Zandwijk N
Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam.
Eur J Cancer. 1992;28A(8-9):1370-3. doi: 10.1016/0959-8049(92)90522-4.
26 patients with inoperable non-small cell lung cancer (NSCLC) were treated with photodynamic therapy (PDT) with intravenous Photofrin II 2 mg/kg. 10 out of 11 stage I patients achieved a complete response. The remaining patient, and 11 out of 15 stage III patients had a partial response. No response was seen in 4 patients, 2 of whom had inadequate illumination. Thus, the objective response rate was 85% (22/26). Although lung function did not improve, dyspnoea was ameliorated in 7 (58%) of the partial responders. 4 stage III patients had tumour progression and died of pulmonary haemorrhages 1.5-6 months after PDT. All had received external irradiation, Nd-YAG laser and/or brachytherapy before PDT. 4 patients had grade I-II skin photosensitivity. Although of value in stage I NSCLC, the clinical benefit of PDT in stage III disease was small.
26例无法手术的非小细胞肺癌（NSCLC）患者接受了光动力疗法（PDT），静脉注射血卟啉单甲醚2毫克/千克。11例I期患者中有10例达到完全缓解。其余1例患者以及15例III期患者中有11例有部分缓解。4例患者无反应，其中2例光照不足。因此，客观缓解率为85%（22/26）。虽然肺功能没有改善，但7例（58%）部分缓解患者的呼吸困难得到了改善。4例III期患者出现肿瘤进展，在PDT后1.5至6个月死于肺出血。所有患者在PDT前均接受过外照射、钕钇铝石榴石激光和/或近距离放射治疗。4例患者有I-II级皮肤光敏反应。虽然PDT对I期NSCLC有价值，但对III期疾病的临床益处较小。
